Novavax (NVAX) Other Non-Current Liabilities (2016 - 2025)
Novavax (NVAX) has 16 years of Other Non-Current Liabilities data on record, last reported at $239.1 million in Q4 2025.
- For Q4 2025, Other Non-Current Liabilities fell 33.52% year-over-year to $239.1 million; the TTM value through Dec 2025 reached $239.1 million, down 33.52%, while the annual FY2025 figure was $239.1 million, 33.52% down from the prior year.
- Other Non-Current Liabilities reached $239.1 million in Q4 2025 per NVAX's latest filing, down from $263.5 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $359.6 million in Q4 2024 and bottomed at $20.6 million in Q2 2021.
- Average Other Non-Current Liabilities over 5 years is $151.4 million, with a median of $67.9 million recorded in 2022.
- Peak YoY movement for Other Non-Current Liabilities: crashed 62.16% in 2023, then surged 985.46% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $42.1 million in 2021, then skyrocketed by 32.23% to $55.7 million in 2022, then crashed by 40.52% to $33.1 million in 2023, then soared by 985.46% to $359.6 million in 2024, then tumbled by 33.52% to $239.1 million in 2025.
- Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $239.1 million in Q4 2025, $263.5 million in Q3 2025, and $287.6 million in Q2 2025.